A pair of studies show that Zepbound can help adults with obesity and overweight achieve sustained and meaningful weight loss ...

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

U.S. drugmaker Eli Lilly has released its Zepbound obesity medication in Japan, targeting the millions said to suffer from the "hidden" scourge of buildups of visceral fat. "We believe there are 16 to ...

Pfizer has encountered many setbacks in its quest to launch a medicine that could rival Wegovy and Zepbound. One of its ...

Eli Lilly's new oral weight loss pill, orforglipron, shows promise in Phase 3 trials, offering a convenient alternative to ...

Ryan Rasmussen was determined to lose weight so he would be around to ski and spend time with his wife and children.

A daily weight loss pill being tested by Eli Lilly could work as well as its GLP-1 injection counterparts like Ozempic, ...

That was music to the ears of investors in Novo Nordisk, which makes diabetes and obesity treatments Ozempic and Wegovy; and in Eli Lilly, which makes Mounjaro and Zepbound diabetes and obesity drugs.

Novo Nordisk, the maker of Ozempic and Wegovy, has also jumped into the legal fight —this time by intervening in the OFA’s lawsuit against the FDA. The company supports the agency’s move to restrict ...

The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a ...

Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.

Patients regularly taking Eli Lilly & Co.’s obesity shot Zepbound tend to keep the weight off for at least three years, with most regaining 5% or less of the pounds they shed. A company-funded ...